MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Innoviva Inc

Fechado

SetorSaúde

18.07 0.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.59

Máximo

18.16

Indicadores-chave

By Trading Economics

Rendimento

19M

20M

Vendas

2.3M

92M

P/E

Médio do Setor

50.361

63.778

EPS

0.26

Margem de lucro

22.147

Funcionários

127

EBITDA

17M

36M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+204.37% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.6M

1.1B

Abertura anterior

18.01

Fecho anterior

18.07

Sentimento de Notícias

By Acuity

50%

50%

353 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Innoviva Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2025, 23:04 UTC

Principais Notícias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 de abr. de 2025, 22:40 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 de abr. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 de abr. de 2025, 18:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 de abr. de 2025, 23:43 UTC

Conversa de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 de abr. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 de abr. de 2025, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 de abr. de 2025, 21:43 UTC

Principais Notícias
Ganhos

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de abr. de 2025, 20:43 UTC

Conversa de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 de abr. de 2025, 20:34 UTC

Principais Notícias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 de abr. de 2025, 20:23 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de abr. de 2025, 19:55 UTC

Conversa de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 de abr. de 2025, 19:21 UTC

Conversa de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 de abr. de 2025, 19:15 UTC

Conversa de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:45 UTC

Conversa de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 de abr. de 2025, 18:39 UTC

Conversa de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 de abr. de 2025, 18:38 UTC

Principais Notícias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 de abr. de 2025, 18:30 UTC

Principais Notícias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 de abr. de 2025, 18:20 UTC

Conversa de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 de abr. de 2025, 18:18 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 de abr. de 2025, 18:17 UTC

Conversa de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 de abr. de 2025, 18:04 UTC

Conversa de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 de abr. de 2025, 17:55 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Innoviva Inc Previsão

Preço-alvo

By TipRanks

204.37% parte superior

Previsão para 12 meses

Média 55 USD  204.37%

Máximo 55 USD

Mínimo 55 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Innoviva Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

17.29 / 18.18Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

353 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.